232 related articles for article (PubMed ID: 10706877)
1. Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells.
Lacronique V; Boureux A; Monni R; Dumon S; Mauchauffé M; Mayeux P; Gouilleux F; Berger R; Gisselbrecht S; Ghysdael J; Bernard OA
Blood; 2000 Mar; 95(6):2076-83. PubMed ID: 10706877
[TBL] [Abstract][Full Text] [Related]
2. TEL/PDGFbetaR fusion protein activates STAT1 and STAT5: a common mechanism for transformation by tyrosine kinase fusion proteins.
Wilbanks AM; Mahajan S; Frank DA; Druker BJ; Gilliland DG; Carroll M
Exp Hematol; 2000 May; 28(5):584-93. PubMed ID: 10812249
[TBL] [Abstract][Full Text] [Related]
3. Fusion of the ets transcription factor TEL to Jak2 results in constitutive Jak-Stat signaling.
Ho JM; Beattie BK; Squire JA; Frank DA; Barber DL
Blood; 1999 Jun; 93(12):4354-64. PubMed ID: 10361134
[TBL] [Abstract][Full Text] [Related]
4. Tyrosyl phosphorylation and DNA binding activity of signal transducers and activators of transcription (STAT) proteins in hematopoietic cell lines transformed by Bcr/Abl.
Carlesso N; Frank DA; Griffin JD
J Exp Med; 1996 Mar; 183(3):811-20. PubMed ID: 8642285
[TBL] [Abstract][Full Text] [Related]
5. Constitutive activation of STAT3 and STAT5 is induced by leukemic fusion proteins with protein tyrosine kinase activity and is sufficient for transformation of hematopoietic precursor cells.
Spiekermann K; Pau M; Schwab R; Schmieja K; Franzrahe S; Hiddemann W
Exp Hematol; 2002 Mar; 30(3):262-71. PubMed ID: 11882364
[TBL] [Abstract][Full Text] [Related]
6. A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia.
Lacronique V; Boureux A; Valle VD; Poirel H; Quang CT; Mauchauffé M; Berthou C; Lessard M; Berger R; Ghysdael J; Bernard OA
Science; 1997 Nov; 278(5341):1309-12. PubMed ID: 9360930
[TBL] [Abstract][Full Text] [Related]
7. TEL-JAK2 mediates constitutive activation of the phosphatidylinositol 3'-kinase/protein kinase B signaling pathway.
Nguyen MH; Ho JM; Beattie BK; Barber DL
J Biol Chem; 2001 Aug; 276(35):32704-13. PubMed ID: 11435425
[TBL] [Abstract][Full Text] [Related]
8. The TEL-Jak2 oncoprotein induces Socs1 expression and altered cytokine response in Ba/F3 cells.
Monni R; Santos SC; Mauchauffe M; Berger R; Ghysdael J; Gouilleux F; Gisselbrecht S; Bernard O; Penard-Lacronique V
Oncogene; 2001 Feb; 20(7):849-58. PubMed ID: 11314018
[TBL] [Abstract][Full Text] [Related]
9. TEL-Syk fusion constitutively activates PI3-K/Akt, MAPK and JAK2-independent STAT5 signal pathways.
Kanie T; Abe A; Matsuda T; Kuno Y; Towatari M; Yamamoto T; Saito H; Emi N; Naoe T
Leukemia; 2004 Mar; 18(3):548-55. PubMed ID: 14749700
[TBL] [Abstract][Full Text] [Related]
10. ARG tyrosine kinase activity is inhibited by STI571.
Okuda K; Weisberg E; Gilliland DG; Griffin JD
Blood; 2001 Apr; 97(8):2440-8. PubMed ID: 11290609
[TBL] [Abstract][Full Text] [Related]
11. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
[TBL] [Abstract][Full Text] [Related]
12. The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2.
Kamizono S; Hanada T; Yasukawa H; Minoguchi S; Kato R; Minoguchi M; Hattori K; Hatakeyama S; Yada M; Morita S; Kitamura T; Kato H; Nakayama Ki ; Yoshimura A
J Biol Chem; 2001 Apr; 276(16):12530-8. PubMed ID: 11278610
[TBL] [Abstract][Full Text] [Related]
13. The TEL/PDGFbetaR fusion in chronic myelomonocytic leukemia signals through STAT5-dependent and STAT5-independent pathways.
Sternberg DW; Tomasson MH; Carroll M; Curley DP; Barker G; Caprio M; Wilbanks A; Kazlauskas A; Gilliland DG
Blood; 2001 Dec; 98(12):3390-7. PubMed ID: 11719379
[TBL] [Abstract][Full Text] [Related]
14. Involvement of the NF-kappaB pathway in the transforming properties of the TEL-Jak2 leukemogenic fusion protein.
Santos SC; Monni R; Bouchaert I; Bernard O; Gisselbrecht S; Gouilleux F; Penard-Lacronique V
FEBS Lett; 2001 May; 497(2-3):148-52. PubMed ID: 11377430
[TBL] [Abstract][Full Text] [Related]
15. Constitutively active STAT5 variants induce growth and survival of hematopoietic cells through a PI 3-kinase/Akt dependent pathway.
Santos SC; Lacronique V; Bouchaert I; Monni R; Bernard O; Gisselbrecht S; Gouilleux F
Oncogene; 2001 Apr; 20(17):2080-90. PubMed ID: 11360192
[TBL] [Abstract][Full Text] [Related]
16. Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes.
Schwaller J; Frantsve J; Aster J; Williams IR; Tomasson MH; Ross TS; Peeters P; Van Rompaey L; Van Etten RA; Ilaria R; Marynen P; Gilliland DG
EMBO J; 1998 Sep; 17(18):5321-33. PubMed ID: 9736611
[TBL] [Abstract][Full Text] [Related]
17. Constitutive activation of the JAK2/STAT5 signal transduction pathway correlates with growth factor independence of megakaryocytic leukemic cell lines.
Liu RY; Fan C; Garcia R; Jove R; Zuckerman KS
Blood; 1999 Apr; 93(7):2369-79. PubMed ID: 10090948
[TBL] [Abstract][Full Text] [Related]
18. Socs-1 inhibits TEL-JAK2-mediated transformation of hematopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation.
Frantsve J; Schwaller J; Sternberg DW; Kutok J; Gilliland DG
Mol Cell Biol; 2001 May; 21(10):3547-57. PubMed ID: 11313480
[TBL] [Abstract][Full Text] [Related]
19. STAT5 activation is required for interleukin-9-dependent growth and transformation of lymphoid cells.
Demoulin JB; Uyttenhove C; Lejeune D; Mui A; Groner B; Renauld JC
Cancer Res; 2000 Jul; 60(14):3971-7. PubMed ID: 10919676
[TBL] [Abstract][Full Text] [Related]
20. TEL-JAK2 constitutively activates the extracellular signal-regulated kinase (ERK), stress-activated protein/Jun kinase (SAPK/JNK), and p38 signaling pathways.
Ho JM; Nguyen MH; Dierov JK; Badger KM; Beattie BK; Tartaro P; Haq R; Zanke BW; Carroll MP; Barber DL
Blood; 2002 Aug; 100(4):1438-48. PubMed ID: 12149229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]